Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
This article was originally published in The Tan Sheet
Executive Summary
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company